
Erasca Inc (ERAS) Stock Forecast & Price Target
Erasca Inc (ERAS) Analyst Ratings
Bulls say
Erasca is a promising precision oncology company with a strong focus on developing effective therapies for RAS/MAPK pathway-driven cancers through three therapeutic strategies. Their collaboration revenue reflects a supportive and collaborative approach to drug development, and with a projected price target of $22 per share based on a solid financial analysis, the company shows great potential for growth in the future. However, risks in regulatory approval, commercialization, clinical development, manufacturing, financial, liability, and intellectual property pose a threat to achieving success. Further clarification on dose strategy by tumor type, safety data, and the planned registrational program will play a vital role in determining the future effectiveness and success of Erasca's pipeline.
Bears say
Erasca is in the clinical stage of drug development for cancer treatments and continues to show promising data in clinical trials; however, the company's pipeline is still far away from potential commercialization. Additionally, the company has incurred significant operating expenses and will need to secure additional funding to continue its development plans. Furthermore, while partnerships with other drug companies are promising, the success of these collaborations is not guaranteed, leading to potential uncertainties in the company's future prospects.
This aggregate rating is based on analysts' research of Erasca Inc and is not a guaranteed prediction by Public.com or investment advice.
Erasca Inc (ERAS) Analyst Forecast & Price Prediction
Start investing in Erasca Inc (ERAS)
Order type
Buy in
Order amount
Est. shares
0 shares